• Home
  • News
  • Personal Finance
    • Savings
    • Banking
    • Mortgage
    • Retirement
    • Taxes
    • Wealth
  • Make Money
  • Budgeting
  • Burrow
  • Investing
  • Credit Cards
  • Loans

Subscribe to Updates

Get the latest finance news and updates directly to your inbox.

Top News

This Beloved Spice Could Be Undermining Your Prescription Meds

May 8, 2025

Top 10 Money Apps That Slash Bills and Build Wealth

May 8, 2025

8 Savings Commandments the Wealthy Secretly Ignore (and Still Get Rich)

May 8, 2025
Facebook Twitter Instagram
Trending
  • This Beloved Spice Could Be Undermining Your Prescription Meds
  • Top 10 Money Apps That Slash Bills and Build Wealth
  • 8 Savings Commandments the Wealthy Secretly Ignore (and Still Get Rich)
  • Fed holds interest rate steady as it waits to see impact of tariffs
  • These Are the Top Food Franchises of 2025
  • Scaling a Business? Think Like a Pilot
  • OpenAI Hires Instacart CEO to Oversee ChatGPT, Applications
  • Money Problems Are a Leading Cause of Divorce. Here’s How To Avoid Them
Friday, May 9
Facebook Twitter Instagram
FintechoPro
Subscribe For Alerts
  • Home
  • News
  • Personal Finance
    • Savings
    • Banking
    • Mortgage
    • Retirement
    • Taxes
    • Wealth
  • Make Money
  • Budgeting
  • Burrow
  • Investing
  • Credit Cards
  • Loans
FintechoPro
Home » ADRs End Mostly Higher, Missfresh and Mesoblast Trade Actively
Investing

ADRs End Mostly Higher, Missfresh and Mesoblast Trade Actively

News RoomBy News RoomAugust 7, 20230 Views0
Facebook Twitter Pinterest LinkedIn WhatsApp Reddit Email Tumblr Telegram

By Denny Jacob

International stocks trading in New York closed mostly higher on Friday.

The S&P/BNY Mellon index of American depositary receipts edged up 0.2% to 156.41. The European index ticked up 0.1% to 149.96. The Asian index climbed 0.3% to 183.83. The Latin American index slipped 0.7% to 202.40, while the emerging-markets index was flat at 303.65.

Missfresh was among those whose ADRs traded actively.

The Chinese online grocery company soared 285% after it reported share-purchase agreements with two investors, an acquisition and the filing of its delayed 2022 annual report.

Mesoblast tumbled 59% after the Food and Drug Administration once again turned away the company’s remestemcel-L drug candidate for children with a potentially life-threatening bone marrow transplant complication, calling on the company to provide more data.

Write to Denny Jacob at [email protected]

Read the full article here

Share. Facebook Twitter Pinterest LinkedIn Tumblr Email

Related Articles

Scaling a Business? Think Like a Pilot

Investing May 8, 2025

How a New Leader Is Reviving a Classic Restaurant Franchise

Investing May 7, 2025

This Healthy Version of Nesquik Is Backed by Ninja and Steve Aoki

Investing May 6, 2025

Think You Know Body Language? These 6 Myths Say Otherwise

Investing May 5, 2025

All-in-One Business Site Builder, CRM, Project Management and More, Now $399

Investing May 4, 2025

These 4 AI Tools Saved Me 20+ Hours a Week—Here’s How to Use Them

Investing May 3, 2025
Add A Comment

Leave A Reply Cancel Reply

Demo
Top News

Top 10 Money Apps That Slash Bills and Build Wealth

May 8, 20250 Views

8 Savings Commandments the Wealthy Secretly Ignore (and Still Get Rich)

May 8, 20250 Views

Fed holds interest rate steady as it waits to see impact of tariffs

May 8, 20250 Views

These Are the Top Food Franchises of 2025

May 8, 20250 Views
Don't Miss

Scaling a Business? Think Like a Pilot

By News RoomMay 8, 2025

Entrepreneur I earned my pilot’s license in college. It wasn’t something I planned — it…

OpenAI Hires Instacart CEO to Oversee ChatGPT, Applications

May 8, 2025

Money Problems Are a Leading Cause of Divorce. Here’s How To Avoid Them

May 8, 2025

Secrets Of Successful Solo Agers

May 8, 2025
Facebook Twitter Instagram Pinterest Dribbble
  • Privacy Policy
  • Terms of use
  • Press Release
  • Advertise
  • Contact
© 2025 FintechoPro. All Rights Reserved.

Type above and press Enter to search. Press Esc to cancel.